• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

shankar.siva@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0003-2840-0658

Prof Shankar Siva

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

519 Scholarly works
7 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Outcomes of stereotactic ablative body radiotherapy for treatment of oligometastatic gynecological cancers: a narrative review
    DOI: 10.1016/j.ijgc.2026.104790
  • 2026

    Journal article

    Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
    DOI: 10.1038/s41467-026-74255-x
  • 2026

    Journal article

    Stereotactic Ablative Radiotherapy (SABR) one stop service for lung cancer: A pilot study for early-stage Non-Small-Cell Lung Cancer (NSCLC)
    DOI: 10.1016/j.radonc.2026.111553
  • 2023

    Research grants (ARC, NHMRC, MRFF)

    Reducing the Impact of Radiation on the Heart for Cancer and Cardiac Disease Patients
  • 2020

    Research grants (other domestic)

    Stereotactic Ablative Body Radiotherapy (Sabr) as a Catalyst to Improve Outcomes From Immunotherapy
  • 2018

    Journal article

    Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
    DOI: 10.2967/jnumed.117.199554
  • 2018

    Research Grant

    Stereotactic Ablative Radiotherapy (Sabr) as a New Precision Treatment Option in Kidney Cancer
Shankar Siva

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
    DOI: 10.1016/j.eururo.2026.03.024
  • 2026

    Journal article

    Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials
    DOI: 10.1016/S1470-2045(26)00170-1
  • 2026

    Journal article

    Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
    DOI: 10.1016/j.jtho.2026.103643
  • 2026

    Journal article

    Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
    DOI: 10.1016/S1470-2045(26)00091-4
  • 2026

    Journal article

    In Reply to Meng et al
    DOI: 10.1016/j.ijrobp.2025.08.006
  • 2026

    Journal article

    Lymph Node Sampling Patterns and Completeness of Staging During Systematic Mediastinal Lymph Node Staging in Patients with Locally Advanced Non-Small-Cell Lung Cancer: A Post Hoc Analysis from the SEISMIC Study
    DOI: 10.3390/cancers18111766
  • 2026

    Journal article

    Oligometastatic RCC: Challenges and Emerging Therapeutic Strategies
    DOI: 10.3390/cancers18121956

RECENT PROJECTS

  • 2025

    Research grants (ARC, NHMRC, MRFF)

    A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224